(Q38387311)

2 September 2017

1 reference

title

Nivolumab: targeting PD-1 to bolster antitumor immunity (English)

1 reference

2 September 2017

Julie R Brahmer

1

1 reference

2 September 2017

Hans Hammers

series ordinal

2

1 reference

2 September 2017

Evan J Lipson

series ordinal

3

1 reference

2 September 2017

language of work or name

English

0 references

publication date

23 March 2015

1 reference

2 September 2017

1 reference

2 September 2017

11

1 reference

2 September 2017

9

1 reference

2 September 2017

1307-1326

1 reference

The blockade of immune checkpoints in cancer immunotherapy

2 September 2017

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

21 January 2018

1 reference

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

21 January 2018

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

Programmed death ligand 2 in cancer-induced immune suppression.

21 January 2018

1 reference

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma

21 January 2018

1 reference

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells

21 January 2018

1 reference

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates

21 January 2018

1 reference

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

21 January 2018

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

21 January 2018

1 reference

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

21 January 2018

1 reference

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors

21 January 2018

1 reference

Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

21 January 2018

1 reference

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy

21 January 2018

1 reference

Gemcitabine-induced severe pulmonary toxicity

21 January 2018

1 reference

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

21 January 2018

1 reference

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma

21 January 2018

1 reference

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.15.52

1 reference

2 September 2017

1 reference